A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
← catalyst calendarNCT07427797 · readout in 118 d
Sponsored by Ipsen (industry) · IPN.PA — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
300estimated
Sites
23
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-27 | actual | When the study began enrolling |
| Primary completion | 2026-12-15 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-15 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-23 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-28 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Moderate to Severe Glabellar Lines
Interventions
- Biological: Corabotase
- Biological: Placebo
Primary outcomes
what the primary-completion date above is the date OFFor North America: Percentage of participants responding to treatment
measured From baseline to week 4
For EU and ROW: Percentage of participants responding to treatment
measured From baseline to week 4
Permalink · IPN.PA's whole pipeline · Catalyst calendar · Every registered study · What changed